热疗联合放疗降低肿瘤α/β值:热放疗与单纯放疗试验的启示
该研究基于三项已发表的荟萃分析,纳入12项热放疗(HTRT)与单纯放疗(RT)对比的临床试验(共864例),覆盖复发性乳腺癌、局部晚期头颈癌和局部晚期宫颈癌。通过计算生物有效剂量(BED)估算临床α/βHTRT值,全局α/βHTRT为2.25 Gy,提示热疗对放疗诱导DNA损伤修复的抑制可降低肿瘤α/β值,应纳入HTRT剂量分割优化。
要点
- 全局α/βHTRT估算为2.25 Gy(SD ±0.79),低于常规假设的α/βRT 10 Gy。
- 复发性乳腺癌、局部晚期头颈癌和局部晚期宫颈癌的α/βHTRT分别为2.05 Gy、1.74 Gy和3.03 Gy。
- 荟萃回归显示α/βHTRT是研究间风险差异的唯一预测因子(系数=-0.096;p=0.03)。
核心结论
- 热疗对放疗诱导DNA损伤修复的热放射生物学效应导致肿瘤α/β值降低。
- 临床应据此优化热放疗的剂量分割方案。
研究设计与样本
- 基于三项已发表的HTRT对比RT荟萃分析,筛选出报告放疗剂量(D)、分次剂量(d)和完全缓解(CR)的研究。
- 共纳入12项试验、864例患者:复发性乳腺癌3项(n=259)、局部晚期头颈癌5项(n=338)、局部晚期宫颈癌4项(n=267)。
- 假设α/βRT为10 Gy计算BEDRT,以BEDRT乘以CRHTRT/CRRT的比值计算BEDHTRT,再按Dd/(BEDHTRT-D)估算α/βHTRT。
主要发现
- 总体风险差异为0.28,支持HTRT(p<0.001)。
- 平均BEDRT为64.7 Gy(SD ±15.5),平均BEDHTRT为109.5 Gy(SD ±32.1)。
- 全局α/βHTRT为2.25 Gy(SD ±0.79);复发性乳腺癌、局部晚期头颈癌和局部晚期宫颈癌分别为2.05 Gy、1.74 Gy和3.03 Gy。
- 荟萃回归中α/βHTRT是研究间风险差异的唯一预测因子(系数=-0.096;p=0.03)。
关键数值与推荐
- 筛选标准:研究需报告放疗剂量(D)、分次剂量(d)及对应完全缓解率(CR)。
- BEDRT计算假设α/βRT为10 Gy。
- α/βHTRT估算公式为Dd/(BEDHTRT-D),其中BEDHTRT=BEDRT×(%CRHTRT/%CRRT)。
临床怎么用
- 热放疗剂量分割设计时应考虑热疗降低肿瘤α/β值的热放射生物学效应。
- 可参考不同瘤种估算的α/βHTRT值(复发性乳腺癌2.05 Gy、局部晚期头颈癌1.74 Gy、局部晚期宫颈癌3.03 Gy)优化临床方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hyperthermia inhibits the repair of irradiation-induced DNA damage and thereby could alter the α/β values of tumours. This study estimates the clinical α/βHTRT values from clinical trials of thermoradiotherapy (HTRT) vs radiotherapy (RT) in recurrent breast (RcBC), head and neck (III/IV) (LAHNC) and cervix cancers (IIB-IVA) (LACC). METHODS: Three recently published meta-analyses for HTRT vs RT in RcBC, LAHNC and LACC were evaluated for complete response (CR). Studies with specified RT dose (D), dose/fraction (d) and corresponding CRs were selected. Tumour biological effective dose (BED) for each study with RT (BEDRT) was computed assuming an α/βRT of 10 Gy. As outcomes were favourable with HTRT, thermoradiobiological BED (BEDHTRT) was calculated as a product of BEDRT and %CRHTRT/%CRRT. The α/βHTRT was estimated as Dd/(BEDHTRT - D). RESULTS: 12 trials with 864 patients were shortlisted - RcBC (3 studies, n = 259), LAHNC (5 studies, n = 338) and LACC (4 studies, n = 267). Overall risk difference of 0.28 favoured HTRT (p < 0.001). Mean BEDRT and BEDHTRT were 64.7 Gy (SD: ±15.5) and 109.5 Gy (SD: ±32.1) respectively and global α/βHTRT was 2.25 Gy (SD: ±0.79). Mean α/βHTRT for RcBC, LAHNC and LACC were 2.05 Gy, 1.74 Gy and 3.03 Gy respectively. On meta-regression, α/βHTRT was the sole predictor for the corresponding risk differences of the studies (coefficient = -0.096; p = 0.03). CONCLUSION: Thermoradiobiological effects on the repair of RT induced DNA damage results in reduction in α/β values of tumours. This should be considered to effectively optimize HTRT dose-fractionation schedules in the clinic.
引用
- Datta NR, Bodis S. Hyperthermia with radiotherapy reduces tumour alpha/beta: Insights from trials of thermoradiotherapy vs radiotherapy alone. Radiother Oncol. 2019. PMID: 31132683. doi:10.1016/j.radonc.2019.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。